FUTAPAN 40 MG (PANTOPRAZOLE) – MEDICAL DESCRIPTION

FUTAPAN is a proton pump inhibitor (PPI) containing pantoprazole, a medication that reduces gastric acid production. It is used in the treatment of acid-related gastrointestinal disorders, including gastroesophageal reflux disease (GERD), erosive esophagitis, and other conditions associated with excessive stomach acid secretion.

FUTAPAN is available in two pharmaceutical formulations:

1. FUTAPAN 40 MG – 28 Enteric-Coated Tablets
2. FUTAPAN 40 MG – Freeze-Dried Powder for Solution for IV Infusion (Vial)

Both formulations contain the same active ingredient but differ in their route of administration and clinical use.

Composition and Pharmaceutical Form

The exact excipients and reconstitution instructions should be checked against the manufacturer's leaflet for each formulation.

Indications and Uses

FUTAPAN may be prescribed for the following conditions:

• Gastroesophageal Reflux Disease (GERD): Helps relieve acid reflux symptoms, including heartburn and acid regurgitation.
• Erosive Esophagitis: Promotes healing of inflammation and damage to the esophageal lining caused by gastric acid.
• Peptic Ulcers: Helps reduce gastric acid secretion, supporting ulcer healing as part of an appropriate treatment regimen.
• Duodenal and Gastric Ulcers: May be used in acid-related ulcer management.
• Helicobacter pylori Eradication: Used in combination with appropriate antibiotics to help eradicate H. pylori and reduce the risk of ulcer recurrence.
• Zollinger–Ellison Syndrome: Helps control excessive gastric acid secretion associated with this condition.

Additional indication for IV formulation:

- Used when oral administration is not possible or appropriate, while providing acid suppression through intravenous administration.

Mechanism of Action

Pantoprazole belongs to the proton pump inhibitor (PPI) class.

It works by:

• Inhibiting the hydrogen-potassium ATPase enzyme system (H+/K+ ATPase), commonly known as the gastric proton pump.
• Blocking the final step of gastric acid production in the stomach.
• Reducing both basal and stimulated gastric acid secretion.
• Increasing gastric pH, creating a favorable environment for healing acid-related damage.

By reducing stomach acidity, pantoprazole helps relieve reflux symptoms and supports the healing of gastric and esophageal lesions.

Dosage and Method of Administration

A. FUTAPAN 40 MG Enteric-Coated Tablets

• The usual adult dose for erosive esophagitis associated with GERD is 40 mg once daily, generally for up to 8 weeks.
• For maintenance of healing, 40 mg once daily may be prescribed.
• Higher or more frequent doses may be required for pathological hypersecretory conditions, depending on the patient's response.
• Tablets should be swallowed whole with water, with or without food.
• Do not crush, chew, or split the enteric-coated tablets.

B. FUTAPAN 40 MG IV Vial

• The usual adult dose for GERD associated with a history of erosive esophagitis is 40 mg once daily.
• IV treatment is generally intended for short-term use, up to 7–10 days depending on the approved product labeling.
• Treatment should be switched to oral pantoprazole as soon as the patient can resume oral medication.
• The vial must be reconstituted and administered by qualified healthcare professionals according to the manufacturer's instructions.
• The administration rate, compatible diluents, and storage conditions of the prepared solution must follow the specific product leaflet.

Important: The dosage for both formulations should be individualized according to the patient's condition and physician's instructions.

Possible Side Effects

Pantoprazole is generally well tolerated. However, some patients may experience:

Common side effects:

• Headache.
• Diarrhea.
• Nausea and vomiting.
• Abdominal pain.
• Flatulence.
• Constipation.
• Dizziness.

Less common or potentially serious adverse effects:

• Allergic reactions, including skin rash and itching.
• Acute interstitial nephritis (kidney inflammation).
• Vitamin B12 deficiency with prolonged use.
• Hypomagnesemia, particularly with long-term treatment.
• Increased risk of certain gastrointestinal infections, including Clostridioides difficile-associated diarrhea.
• Bone fractures, particularly with prolonged or high-dose therapy in susceptible patients.
• Severe skin reactions, although rare.

Seek medical attention if severe allergic reactions, persistent diarrhea, unusual muscle weakness, or signs of kidney problems develop.

Contraindications and Precautions

FUTAPAN should not be used in patients with:

• Known hypersensitivity to pantoprazole or other substituted benzimidazoles.
• Hypersensitivity to any component of the formulation.
• Concomitant use of rilpivirine-containing products.

Special precautions:

• Patients with severe liver impairment may require medical monitoring and dose adjustment.
• Long-term use should be periodically reviewed by a healthcare professional.
• Prolonged treatment may require monitoring of magnesium and vitamin B12 levels in patients at risk.
• Persistent or unexplained gastrointestinal symptoms require appropriate medical evaluation.
• Pantoprazole may mask symptoms of certain gastric conditions, including stomach malignancy.
• Patients with osteoporosis risk factors should discuss prolonged PPI therapy with their physician.

Drug Interactions

Pantoprazole may interact with medications whose absorption or effectiveness is affected by changes in stomach acidity.

Important interactions include:

• Rilpivirine: Concomitant use is contraindicated.
• Warfarin: May require monitoring of INR and prothrombin time.
• Methotrexate: High-dose methotrexate may have increased exposure when used with PPIs.
• Certain antifungal medications: Such as ketoconazole and itraconazole, whose absorption may be reduced.
• Atazanavir and other pH-dependent antiretroviral medications: Their absorption may be affected.
• Iron salts: Absorption may be reduced in some patients.

Patients should inform their healthcare provider about all medications and supplements they are taking before starting FUTAPAN.

Pregnancy and Breastfeeding

• Pregnancy: Use only when considered necessary by the treating physician after evaluating potential benefits and risks.
• Breastfeeding: Consult a healthcare professional before use to assess the suitability of treatment.

The decision should be based on the patient's individual clinical circumstances.

Storage Conditions

Enteric-coated tablets:

• Store below the temperature specified on the original package.
• Protect from moisture and direct sunlight.
• Keep in the original packaging until use.

IV freeze-dried powder:

• Store according to the manufacturer's recommended temperature and conditions.
• Protect the vial from inappropriate storage conditions.
• Reconstituted and diluted solutions must be stored and used within the time limits specified in the product leaflet.
• Do not use solutions showing unexpected discoloration or particulate matter.

Keep both formulations out of reach of children.

Patient Disclaimer

This description is intended for educational and informational purposes only. It does not replace professional medical advice, diagnosis, or treatment.

FUTAPAN should be used according to the instructions of a qualified healthcare professional. Do not exceed the prescribed dosage or discontinue long-term treatment without consulting your physician.

The IV formulation must only be prepared and administered by qualified healthcare professionals. Consult your doctor or pharmacist if symptoms persist, worsen, or are accompanied by difficulty swallowing, unexplained weight loss, vomiting blood, or black stools.

References

1. U.S. FDA – DailyMed: Pantoprazole sodium delayed-release tablets: indications, dosage, contraindications, warnings, and adverse reactions. Pantoprazole – FDA/DailyMed.
2. U.S. FDA – DailyMed: Pantoprazole sodium for injection: IV indications, dosage, preparation, administration, and safety information. Pantoprazole IV – Prescribing Information.
3. Pfizer – Official Prescribing Information: Protonix and Protonix IV, including pharmacological properties and clinical precautions. Protonix IV – Official Prescribing Information.
4. U.S. National Library of Medicine (NCBI): Pantoprazole drug information and clinical pharmacology. Pantoprazole – NCBI.
5. U.S. National Library of Medicine: Pantoprazole injection formulation and administration guidance. Pantoprazole Injection – DailyMed.